Deutsch English Français

Contact

EP3038655

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3038655

EP3038655 - METHOD AND PRODUCTS FOR ENHANCING CELLULAR UPTAKE OF DRUG AND DIETARY SUPPLEMENTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 18.12.2020 Database last updated on 19.10.2024
Former	Examination is in progress Status updated on 07.02.2020
Most recent event Tooltip	18.12.2020	Application deemed to be withdrawn	published on 20.01.2021 [2021/03]
Applicant(s)	For all designated states CBA Pharma Inc. 670 Perimeter Drive Lexington, KY 40517 / US
	[2016/27]
Inventor(s)	01 / BARNETT, Daryl, L. 1037 Crimson Creek Drive Lexington, KY 40509 / US
	[2016/27]
Representative(s)	FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 / IE
	[N/P]
Former [2016/27]	Hally, Anna-Louise FRKelly 27 Clyde Road Dublin 4 / IE
Application number, filing date	14770474.6	12.03.2014
	[2016/27]
	WO2014US24649
Priority number, date	US201361793028P	15.03.2013 Original published format: US 201361793028 P
	[2016/27]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2014150959
	Date:	25.09.2014
	Language:	EN
	[2014/39]
	Type:	A2 Application without search report
	No.:	EP3038655
	Date:	06.07.2016
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 25.09.2014 takes the place of the publication of the European patent application.
	[2016/27]
Search report(s)	International search report - published on:	US	22.01.2015
	(Supplementary) European search report - dispatched on:	EP	16.12.2016
Classification	IPC:	A61K45/06, A61K31/4741, A61K31/4725	[2016/27]
	CPC:	A61K45/06 (EP,US); A23L33/10 (EP,US); A61K31/4745 (EP,US)
	C-Set:	A61K31/4745, A61K2300/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/27]
Title	German:	VERFAHREN UND PRODUKTE ZUR VERSTÄRKUNG DER ZELLULÄREN AUFNAHME VON ARZNEIMITTELN UND NAHRUNGSERGÄNZUNGSMITTELN	[2016/27]
	English:	METHOD AND PRODUCTS FOR ENHANCING CELLULAR UPTAKE OF DRUG AND DIETARY SUPPLEMENTS	[2016/27]
	French:	PROCÉDÉ ET PRODUITS POUR ACCROÎTRE L'ABSORPTION CELLULAIRE DE MÉDICAMENTS ET DE COMPLÉMENTS ALIMENTAIRES	[2016/27]
Entry into regional phase	14.10.2015	National basic fee paid
	14.10.2015	Search fee paid
	14.10.2015	Designation fee(s) paid
	14.10.2015	Examination fee paid
Examination procedure	14.10.2015	Examination requested [2016/27]
	17.07.2017	Amendment by applicant (claims and/or description)
	11.02.2020	Despatch of a communication from the examining division (Time limit: M06)
	22.08.2020	Application deemed to be withdrawn, date of legal effect [2021/03]
	11.09.2020	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/03]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 11.02.2020
Fees paid	Renewal fee
	20.09.2016	Renewal fee patent year 03
	27.02.2017	Renewal fee patent year 04
	26.06.2018	Renewal fee patent year 05
	15.02.2019	Renewal fee patent year 06
	29.09.2020	Renewal fee patent year 07
	Penalty fee
	Additional fee for renewal fee
	31.03.2016	03 M06 Fee paid on 20.09.2016
	31.03.2018	05 M06 Fee paid on 26.06.2018
	31.03.2020	07 M06 Fee paid on 29.09.2020
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO9218131 (CBA INT INC [US]) [X] 1-7,9-15 * the whole document *;
		[X]US5332747 (VAN DYKE KNOX [US]) [X] 1-7,9-15 * the whole document *;
		[X]US6124315 (VAN DYKE KNOX [US]) [X] 1-15 * the whole document *;
		[X]US6962927 (VAN DYKE KNOX [US]) [X] 1-7,9-15 * abstract * * column 2, line 61 - column 12, line 20 *;
		[E]US2014073591 (GUDEMAN BETH D [US], et al) [E] 1-15* the whole document *;
		[X] - Young-Seob Lee ET AL, "Synergistic effect of tetrandrine and ethidium bromide against methicillin-resistant Staphylococcus aureus (MRSA)", The Journal of Toxicological Sciences The Journal of Toxicological Sciences Vol. 36 (2011) No. 5 October P 645-651, (20110101), URL: https://www.jstage.jst.go.jp/article/jts/36/5/36_5_645/_pdf, (20161208), XP055327425 [X] 1-15 * the whole document * DOI: http://dx.doi.org/10.2131/jts.36.645
		[X] - GUO-YING ZUO ET AL, "Synergistic Antibacterial and Antibiotic Effects of Bisbenzylisoquinoline Alkaloids on Clinical Isolates of Methicillin-Resistant Staphylococcus Aureus (MRSA)", MOLECULES, (20111125), vol. 16, no. 12, doi:10.3390/molecules16129819, pages 9819 - 9826, XP055327353 [X] 1-15 * the whole document * DOI: http://dx.doi.org/10.3390/molecules16129819
		[X] - XU W L ET AL, "Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 30, no. 4, ISSN 0145-2126, (20060401), pages 407 - 413, (20060401), XP027941634 [X] 1-7,9-15 * abstract *
		[X] - YONG-QIANG SHAN ET AL, "Tetrandrine Potentiates the Hypoglycemic Efficacy of Berberine by Inhibiting P-Glycoprotein Function", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), JP, (20130101), vol. 36, no. 10, doi:10.1248/bpb.b13-00272, ISSN 0918-6158, pages 1562 - 1569, XP055327445 [X] 1-7,9-15 * abstract * DOI: http://dx.doi.org/10.1248/bpb.b13-00272
		[X] - JIAN-PING SHI ET AL, "Synergistic effects of tetrandrine on the antifungal activity of topical ketoconazole cream in the treatment of dermatophytoses: A clinical trial", CHINESE JOURNAL OF INTEGRATIVE MEDICINE, CHINESE ASSOCIATION OF TRADITIONAL AND WESTERN MEDICINE, HEIDELBERG, (20110703), vol. 17, no. 7, doi:10.1007/S11655-010-0782-3, ISSN 1993-0402, pages 499 - 504, XP019925412 [X] 1-7,9-15 * the whole document * DOI: http://dx.doi.org/10.1007/s11655-010-0782-3
		[X] - FU L W ET AL, "The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, (20020101), vol. 38, no. 3, doi:10.1016/S0959-8049(01)00356-2, ISSN 0959-8049, pages 418 - 426, XP004333826 [X] 1-7,9-15 * abstract * DOI: http://dx.doi.org/10.1016/S0959-8049(01)00356-2
	International search	[Y]WO9218131 (CBA INT INC [US]);
		[Y]US6086915 (ZELIGS MICHAEL A [US], et al);
		[A]US6350476 (HOU LIPING [CN])
	by applicant	WO9218131
		US5332747
		US6124315
		US6962927
		- YOUNG-SEOB LEE, Synergistic effect of tetrandrine and ethidium bromide against MRSA
		- XU, Combination of tetrandrine as a potential-reversing agent with daunorubicin ...
		- SHI JIAN-PING, Synergistic Effects of Tetrandrine on the Antifungal Activity of Topical Ketoconazole Cream in the Treatment of Dermatophytoses
		- L.W. FU et al., The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p